Pathophysiology-Based Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome: Implementing Predictive, Preventive, and Personalized Medical Approach

Bubnov, Rostyslav; Spivak, Mykola

doi:10.1007/978-3-031-19564-8_6

Cited by 4 publications

(3 citation statements)

References 279 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The modification of the gut microbiota in metabolic syndrome and associated chronic diseases is among the leading tasks of microbiome research and is needed for the clinical use of probiotics [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

“…Studies also discovered the possible link between the gut microbiota and glaucoma, for example: irritable bowel disease patients have higher risk of glaucoma [ 32 ], and there is distinct difference in gut microbiota composition and serum metabolic phenotype between POAG patients and healthy individuals [ 33 , 34 ]. Thus, the modification of the gut microbiota in metabolic syndrome and its related chronic diseases stands as a prominent objective within the realm of microbiome research, with the aim of enabling the clinical application of probiotics [ 35 , 36 ]. The increasing scientific and clinical evidence highlight the impact of microbial influence on distal sites such as the skin, heart, and central nervous system [ 37 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine

et al. 2023

View full text Add to dashboard Cite

Background Glaucoma is the leading cause of irreversible blindness worldwide. Emerged evidence has shown that glaucoma is considered an immune system related disorder. The gut is the largest immune organ in the human body and the gut microbiota (GM) plays an irreversible role in maintaining immune homeostasis. But, how the GM influences glaucoma remains unrevealed. This study aimed at investigating the key molecules/pathways mediating the GM and the glaucoma to provide new biomarkers for future predictive, preventive, and personalized medicine. Methods Datasets from the primary open-angle glaucoma (POAG) patients (GSE138125) and datasets for target genes of GM/GM metabolites were downloaded from a public database. For GSE138125, the differentially expressed genes (DEGs) between healthy and POAG samples were identified. And the online Venn diagram tool was used to obtain the DEGs from POAG related to GM. After which GM-related DEGs were analyzed by correlation analysis, pathway enrichment analysis, and protein–protein interaction (PPI) network analysis. Human trabecular meshwork cells were used for validation, and the mRNA level of hub genes was verified by quantitative real-time polymerase chain reaction (RT-qPCR) in the in vitro glaucoma model. Results A total of 16 GM-related DEGs in POAG were identified from the above 2 datasets (9 upregulated genes and 7 downregulated genes). Pathway enrichment analysis indicated that these genes are mostly enriched in immune regulation especially macrophages-related pathways. Then 6 hub genes were identified by PPI network analysis and construction of key modules. Finally, RT-qPCR confirmed that the expression of the hub genes in the in vitro glaucoma model was consistent with the results of bioinformatics analysis of the mRNA chip. Conclusion This bioinformatic study elucidates NFKB1, IL18, KITLG, TLR9, FKBP2, and HDAC4 as hub genes for POAG and GM regulation. Immune response modulated by macrophages plays an important role in POAG and may be potential targets for future predictive, preventive, and personalized diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Due to the unique composition of the microbiota of each person, an individual approach based on stratifi cation (division of patients into groups with diff erent characteristics of the qualitative and quantitative composition of the intestinal microbiota) of the intestinal microbiome is necessary. Th e use of functional food products enriched with microencapsulated highly eff ective probiotic microorganisms is based on the conception of 3p -pathophysiology-based individualized use of probiotics and prebiotics for metabolic syndrome: implementing a predictive, preventive, and personalized medical approach [76].…”

Section: Encapsulated Probiotic Microorganisms In the Food Industrymentioning

confidence: 99%

Encapsulated Probiotic Microorganisms in Functional Food Products

Starovoitova,

Kishko,

Demchenko

et al. 2023

Mikrobiol. Z.

View full text Add to dashboard Cite

Alterations in the composition of the gut microbiota are associated with a wide range of pathologies, including not only inflammatory diseases of the gastrointestinal tract, but also diabetes, obesity, cancer, and diseases of the cardiovascular and central nervous systems. With an imbalance of the microbiota (dysbiosis), there is increased intestinal permeability and a violation of local or systemic immune responses. One of the possible ways to improve intestinal microbiota is the use of dietary supplements and functional food products enriched with highly effective encapsulated probiotic microorganisms, as well as prebiotic compounds. Such products contribute to the restoration of normal intestinal microflora and its integrity, and also indirectly affect the positive outcome in the treatment of many pathological conditions mediated by an imbalance in the intestinal microbiota. Maintaining the activity of probiotics in food carriers or functional food products designed for the prevention and complex therapy of various pathological conditions is important both for the normalization of the intestinal microflora and the health of the body as a whole. In this context, encapsulation is an effective approach to maintain the viability and stability of probiotics under adverse conditions in the gastrointestinal tract and also an effective way to protect from processing conditions, temperature, and transportation. The development of functional nutrition products enriched with highly effective encapsulated probiotic microorganisms is a priority for new research in the field of prevention and treatment in microbiota-targeted therapy. The use of such products is based on the conception of 3p — pathophysiology-based individualized use of probiotics and prebiotics in various pathological conditions mediated by a violation of the qualitative and/or quantitative composition of the intestinal microbiota: implementing a predictive, preventive, and personalized medical approach.

show abstract

Genetically predicted the causal relationship between gut microbiota and infertility: bidirectional Mendelian randomization analysis in the framework of predictive, preventive, and personalized medicine

Zhang

Feng

et al. 2023

EPMA Journal

View full text Add to dashboard Cite

Pathophysiology-Based Individualized Use of Probiotics and Prebiotics for Metabolic Syndrome: Implementing Predictive, Preventive, and Personalized Medical Approach

Cited by 4 publications

References 279 publications

The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine

The correlation between primary open-angle glaucoma (POAG) and gut microbiota: a pilot study towards predictive, preventive, and personalized medicine

Encapsulated Probiotic Microorganisms in Functional Food Products

Genetically predicted the causal relationship between gut microbiota and infertility: bidirectional Mendelian randomization analysis in the framework of predictive, preventive, and personalized medicine

Contact Info

Product

Resources

About